Literature DB >> 15827171

H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity.

An Chen1, Li Wang, Jingbo Zhang, Liyun Zou, Zhengcai Jia, Wei Zhou, Ying Wan, Yuzhang Wu.   

Abstract

It is necessary to evaluate the cytokine secretion status of CD8+ T lymphocytes and elucidate the factors influencing cytokine secretion, because the secretion of cytokines is also an important feature of CD8+ T lymphocytes, and the cytokines usually play critical roles in the outcome of diseases. We showed here that peptide AYRPPNAPI, derived from the core antigen of hepatitis B virus (HBV), could bind to H-2 Kd and induce primed splenocytes from HBcAg expression plasmid-immunized mice to produce gamma interferon (IFN-gamma) in H-2 Kd- and CD8-dependent manners instead of in a CD4-dependent manner. The induced cells were mainly CD3 and CD8 positive but had no cytotoxic effect on the corresponding target cells. When administered into HBV transgenic mice, these cells can decrease the serum HBV load without causing liver damage. These results suggest that this peptide is a special kind of CD8+ T-cell epitope, for which specific CD8+ T cells can produce IFN-gamma when antigenic stimulation is encountered but which have no cytotoxic effect on the corresponding target cells both in vitro and in HBV transgenic mice. This phenomenon indicates initially that the functional mechanisms of CD8+ T cells can be determined by their epitope specificity, which may be associated with the development of epitope-based immunotherapeutic approaches for infectious diseases and tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827171      PMCID: PMC1082734          DOI: 10.1128/JVI.79.9.5568-5576.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Epitope affinity for MHC class I determines helper requirement for CTL priming.

Authors:  A Franco; D A Tilly; I Gramaglia; M Croft; L Cipolla; M Meldal; H M Grey
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

Review 2.  Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens.

Authors:  M Schirle; T Weinschenk; S Stevanović
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

3.  A simple method to reduce the background and improve well-to-well reproducibility of staining in ELISPOT assays.

Authors:  A Kalyuzhny; S Stark
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

Review 4.  Lymphocyte-mediated cytotoxicity.

Authors:  John H Russell; Timothy J Ley
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 5.  Prospects for vaccine protection against HIV-1 infection and AIDS.

Authors:  Norman L Letvin; Dan H Barouch; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

6.  High peptide affinity for MHC class I does not correlate with immunodominance.

Authors:  A Müllbacher; M Lobigs; J W Yewdell; J R Bennink; R Tha Hla; R V Blanden
Journal:  Scand J Immunol       Date:  1999-10       Impact factor: 3.487

7.  Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection.

Authors:  T Lancaster; E Sanders; J M L Christie; C Brooks; S Green; W M C Rosenberg
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

8.  Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Authors:  Kazuhiro Kakimi; Masanori Isogawa; JoSan Chung; Alessandro Sette; Francis V Chisari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 9.  Cytotoxic T lymphocytes: all roads lead to death.

Authors:  Michele Barry; R Chris Bleackley
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

10.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

View more
  5 in total

1.  Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.

Authors:  Tracy D Reynolds; Linda Buonocore; Nina F Rose; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

2.  Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the MicroRNA 15a/16 cluster.

Authors:  Ningning Liu; Jinfang Zhang; Tong Jiao; Zhiwei Li; Jirun Peng; Zhuqingqing Cui; Xin Ye
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

3.  Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.

Authors:  Frederick Arce; Karine Breckpot; Holly Stephenson; Katarzyna Karwacz; Michael R Ehrenstein; Mary Collins; David Escors
Journal:  Arthritis Rheum       Date:  2011-01

4.  Identification of CD4 and H-2Kd-restricted cytotoxic T lymphocyte epitopes on the human herpesvirus 6B glycoprotein Q1 protein.

Authors:  Satoshi Nagamata; Taiki Aoshi; Akiko Kawabata; Yoshiaki Yamagishi; Mitsuhiro Nishimura; Soichiro Kuwabara; Kouki Murakami; Hideto Yamada; Yasuko Mori
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

Review 5.  A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus.

Authors:  Yandan Wu; Yan Ding; Chuanlai Shen
Journal:  Vaccines (Basel)       Date:  2022-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.